

GPR65 Antibody (C-term) Blocking Peptide

Synthetic peptide Catalog # BP9501b

Specification

GPR65 Antibody (C-term) Blocking Peptide - Product Information

Primary Accession

Q8IYL9

GPR65 Antibody (C-term) Blocking Peptide - Additional Information

Gene ID 8477

Other Names

Psychosine receptor, G-protein coupled receptor 65, T-cell death-associated gene 8 protein, GPR65, TDAG8

Format

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

Storage

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

Precautions

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

GPR65 Antibody (C-term) Blocking Peptide - Protein Information

Name GPR65

Synonyms TDAG8

Function

Receptor for the glycosphingolipid psychosine (PSY) and several related glycosphingolipids (PubMed:11309421). Plays a role in immune response by maintaining lysosome function and supporting phagocytosis-mediated intracellular bacteria clearance (PubMed:27287411). May have a role in activation-induced cell death or differentiation of T-cells (By similarity).

Cellular Location

Cell membrane; Multi-pass membrane protein

Tissue Location

Predominantly expressed in thymus, spleen, lymph nodes, small intestine, lung, placenta and peripheral blood leukocytes



GPR65 Antibody (C-term) Blocking Peptide - Protocols

Provided below are standard protocols that you may find useful for product applications.

• Blocking Peptides

GPR65 Antibody (C-term) Blocking Peptide - Images

GPR65 Antibody (C-term) Blocking Peptide - Background

Receptor for the glycosphingolipid psychosine (PSY) and several related glycosphingolipids. May have a role in activation-induced cell death or differentiation of T-cells.

GPR65 Antibody (C-term) Blocking Peptide - References

Mogi, C., et al. J. Immunol. 182(5):3243-3251(2009)Ishii, S., et al. J. Biol. Chem. 280(10):9083-9087(2005)Radu, C.G., et al. Proc. Natl. Acad. Sci. U.S.A. 102(5):1632-1637(2005)